Citi analyst Yigal Nochomovitz raised the firm’s price target on Arcturus Therapeutics to $48 from $40 and keeps a Buy rating on the shares. The analyst cites the inclusion of Japan-specific revenues for ARCT-154 for the target increase. Based on current vaccination trendlines in Japan, the Japanese government needs to meet demand for 15M additional booster doses in 2024, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARCT:
- Arcturus Therapeutics management to meet with Piper Sandler
- Arcturus Therapeutics’ and CSL’s COVID-19 vaccine shows longer immune response
- Biotech Alert: Searches spiking for these stocks today
- 3 Best Stocks to Buy Now, 1/15/2024, According to Top Analysts
- PassPort Technologies starts collaborative research with Arcturus Therapeutics